Evidence & regulatory context
- Mechanism
- Immunomodulatory polysaccharide fraction from Echinacea; botanical macromolecule.
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseEndotoxin/LPSC57BL/65 mg/kg or 10 mg/kg in vivo; 100 micrograms/mL in RAW 264.7…Administered after lipopolysaccharide induction in vivo; in vitro cells pretrea…
Model: Acute lung injury induced with lipopolysaccharide 2.5 mg/kg
Echinacea polysaccharide reduced lipopolysaccharide-induced lung pathological damage, lung wet to dry weight ratio and myeloperoxidase activity, and lowered leukocyte, eosinophil, neutrophil, lymphocyte and macrophage counts in bronchoalveolar lavage fluid. It reduced TNF-alpha, IL-6 and IL-1beta i…
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.